Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$24.37
+0.2%
$19.47
$16.10
$41.94
$3.07B0.782.90 million shs1.34 million shs
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$12.22
-9.2%
$10.69
$5.00
$16.85
$787.84M1.51.72 million shs1.97 million shs
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$15.00
-8.0%
$16.40
$11.51
$21.50
$2.84B0.5538,920 shs129,176 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$25.64
+2.6%
$34.47
$24.28
$55.33
$1.51B2.361.39 million shs1.97 million shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
+0.16%+6.19%+26.86%+40.87%-27.45%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-7.88%+0.33%+10.49%+57.68%-19.61%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
-8.03%-13.14%-7.98%+5.19%-23.59%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+2.56%-23.87%-34.46%-16.81%-42.45%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
4.7068 of 5 stars
4.33.00.04.43.72.50.6
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
1.2971 of 5 stars
1.03.00.00.02.72.51.3
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
2.9925 of 5 stars
3.34.00.00.02.40.01.9
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.543 of 5 stars
3.40.00.04.43.10.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2.58
Moderate Buy$34.1240.00% Upside
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
2.00
Hold$8.50-30.44% Downside
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
2.50
Moderate Buy$28.0086.67% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.73
Moderate Buy$49.4092.67% Upside

Current Analyst Ratings Breakdown

Latest DNA, TWST, APLS, and HCM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/4/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/4/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$46.00
8/4/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$35.00 ➝ $37.00
8/1/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$17.00 ➝ $19.00
8/1/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$39.00 ➝ $40.00
8/1/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$52.00 ➝ $50.00
7/29/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$41.00 ➝ $46.00
7/22/2025
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$27.00 ➝ $28.00
7/18/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$47.00 ➝ $50.00
7/16/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$23.00 ➝ $24.00
7/2/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$25.00 ➝ $26.00
(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$781.37M3.94N/AN/A$1.24 per share19.65
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$227.04M3.15N/AN/A$13.17 per share0.93
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$630.20M4.15$0.26 per share56.78$4.43 per share3.39
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$312.97M4.94N/AN/A$7.92 per share3.24
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-$197.88M-$1.82N/AN/AN/A-30.24%-116.09%-26.72%N/A
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$547.03M-$9.16N/AN/AN/A-136.56%-41.63%-21.67%N/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
$37.73MN/A0.0010.27N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$1.45N/AN/AN/A-23.51%-29.03%-21.77%N/A

Latest DNA, TWST, APLS, and HCM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$1.44-$1.10+$0.34-$1.10$41.60 million$49.60 million
8/4/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54-$0.47+$0.07$0.33$95.52 million$96.06 million
7/31/2025Q2 2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-$0.44-$0.33+$0.11-$0.33$187.91 million$171.39 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
N/AN/AN/AN/AN/A
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/AN/AN/AN/AN/A
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2.90
3.77
3.16
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/A
4.88
4.88
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
0.08
2.83
2.70
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
3.90
4.24

Institutional Ownership

CompanyInstitutional Ownership
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
96.29%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
78.63%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
8.82%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
6.50%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
9.72%
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
3.60%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
770126.29 million118.08 millionOptionable
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
64058.53 million52.84 millionOptionable
HUTCHMED (China) Limited Sponsored ADR stock logo
HCM
HUTCHMED
1,811174.42 million168.14 millionNot Optionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99060.36 million58.54 millionOptionable

Recent News About These Companies

Leerink Partnrs Has Positive Outlook of TWST FY2025 Earnings
What is William Blair's Forecast for TWST FY2025 Earnings?
FY2025 Earnings Estimate for TWST Issued By Leerink Partnrs
Twist Bioscience (TWST) Q3 Profit Surges
Twist Bioscience Corporation (NASDAQ:TWST) Short Interest Update

New MarketBeat Followers Over Time

Media Sentiment Over Time

Apellis Pharmaceuticals stock logo

Apellis Pharmaceuticals NASDAQ:APLS

$24.37 +0.04 (+0.16%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$23.70 -0.68 (-2.77%)
As of 08/8/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Ginkgo Bioworks stock logo

Ginkgo Bioworks NYSE:DNA

$12.22 -1.24 (-9.21%)
Closing price 08/8/2025 03:59 PM Eastern
Extended Trading
$12.82 +0.60 (+4.95%)
As of 08/8/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

HUTCHMED stock logo

HUTCHMED NASDAQ:HCM

$15.00 -1.31 (-8.03%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$15.07 +0.07 (+0.47%)
As of 08/8/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$25.64 +0.64 (+2.56%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$25.50 -0.14 (-0.53%)
As of 08/8/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.